India Healthcare Market Report Key Takeaways

• The India Healthcare Market size was valued at USD 416 billion in 2025 and is projected to grow from USD 498 billion in 2026 to USD 719 billion by 2032, exhibiting a CAGR of 6.31% during the forecast period.
• Out of India’s total patient population of 48,525,391,591, an estimated 112,003,578 individuals are living with diabetes, reflecting its significant burden
• Cardiovascular diseases account for an estimated 77,799,236 of India’s total patient population of 48,525,391,591, reflecting a significant public health concern.
• India’s healthcare system is supported by approximately 1.3–1.5 physicians per 1,000 populations, including both allopathic and AYUSH practitioners, along with around 2.0–2.3 nurses per 1,000 populations. The country has nearly 65,000–75,000 hospitals and healthcare facilities across public and private sectors, and about 1.3–1.9 million hospital beds, reflecting limited per-capita capacity. Diagnostic infrastructure is relatively strong in urban centers, with widespread availability of advanced technologies such as MRI and CT scanners in major tertiary and corporate hospitals, while access remains more constrained in rural and semi-urban regions, highlighting a system that is large in scale but uneven in distribution.

India Healthcare Market Size and Outlook

The India Healthcare Market, valued at approximately USD 416 billion in 2025, is expected to grow steadily to around USD 498 billion in 2026, further reaching nearly USD 719 billion by 2032. This expansion reflects a consistent growth trajectory, with the market projected to register a CAGR of 6.31% during the forecast period.

India’s health system is witnessing sustained expansion driven by rising patient volumes, epidemiological transitions, and infrastructure scaling across institutional providers. As per the Ministry of Health and Family Welfare, over 32,574 hospitals are empaneled under public insurance frameworks as of 2025, reflecting significant capacity expansion. Meanwhile, India continues to face a shortage of hospital beds, with density ranging between 1.5–1.6 beds per 1,000 population, below global benchmarks, indicating strong unmet demand. The growing burden of non-communicable diseases, such as cardiovascular conditions, diabetes, and cancer, is increasing long-term patient inflow into hospitals and specialized care facilities.

Government-backed healthcare expansion is significantly strengthening institutional demand across public and semi-urban healthcare systems. Under Ayushman Bharat, more than 42 crore health cards have been issued, and over 9.64 crore hospital admissions have been funded as of 2025, directly increasing healthcare utilization.

Additionally, more than 178,000 Health and Wellness Centres are operational, expanding primary care access and early disease detection across rural regions. These initiatives are driving patient footfall in institutional healthcare settings, particularly among economically weaker populations, while improving service penetration across underserved geographies.

The Healthcare workforce and service delivery capacity are also improving, supporting long-term sector scalability. India’s doctor-to-population ratio has improved to 1:811, surpassing the WHO benchmark of 1:1000, alongside a nursing workforce exceeding 3.9 million professionals.

This expansion is critical in addressing rising disease complexity, including genetic and chronic disorders, which require specialized clinical expertise and long-term care infrastructure. Institutional end-users such as hospitals and diagnostic centers are therefore expanding advanced treatment capabilities, further increasing demand for high-value healthcare services.

According to the department of Pharmaceuticals, India ranks 3rd globally in pharmaceutical production by volume, exports medicines to 200+ countries, including US, EU, Japan, has one of the largest numbers of USFDA-approved plants outside the US. India plays a central role in the global pharmaceutical supply chain, accounting for approximately 20% of worldwide generic medicine supply by volume and nearly 60% of global vaccine production, reflecting its strong international market presence and manufacturing competitiveness. These figures underscore India’s position as a major global supplier of affordable medicines and vaccines, reinforcing its strategic importance in global healthcare delivery.

India is witnessing a measurable increase in the diagnosis of genetic and inherited disorders, primarily due to the expansion of large-scale screening programs and improved diagnostic infrastructure led by the Indian Council of Medical Research. Sickle cell disease (SCD) has emerged as one of the most significant genetic health burdens, with India accounting for 82,500 affected births annually, representing a substantial share of global cases. In response, the government has initiated nationwide screening efforts under targeted programs, with states like Odisha screening over 4.6 million individuals and identifying more than 97,000 confirmed cases within two years, reflecting rapid detection expansion.

Similarly, thalassemia continues to be a major inherited blood disorder in India, with increasing case identification driven by digital registries and national monitoring systems. Government-supported screening initiatives and funding under national health missions are improving e arly detection and treatment access, including financial assistance for advanced procedures such as bone marrow transplants. Overall, the expansion of genomic research, population-scale screening programs, and institutional diagnostics is significantly increasing the detection of genetic and rare diseases across India. This is directly contributing to higher demand for specialized treatments, long-term care infrastructure, and precision medicine services, reinforcing the growth trajectory of the healthcare sector.

India Healthcare Industry Key Indicators

• India has nearly 70,000 operational hospitals (63% privately owned), with a bed-to-population ratio of 1.3 per 1,000, well below the WHO's recommendation of 3 beds per 1,000. Government hospitals alone stand at 0.79 beds per 1,000. This shortage is driving rapid private sector expansion, hospital chain investments, and capacity addition in Tier-1 and Tier-2 cities, as demand far exceeds public system capability. It is also accelerating growth in private healthcare, insurance penetration, and medical infrastructure funding, since patients are increasingly dependent on private providers for timely care.
• As of April 1, 2025, India has 13,86,150 registered allopathic doctors and 7,51,768 AYUSH practitioners, resulting in a doctor-to-population ratio of 1:811. This growing doctor base is improving access to medical care across both urban and rural regions, while also supporting the rapid expansion of hospitals, clinics, and digital consultation platforms. It is enabling faster diagnosis, better patient coverage, and wider availability of specialist services across Tier-2 and Tier-3 cities.
• The sector is valued at USD12 billion (FY2023–24) with a government target of USD 50 billion by 2030. As of late 2024, PLI programmes for pharmaceuticals and devices have catalysed over ₹33,500 crore of industrial investment , nearly double initial projections, with 78 manufacturing projects approved.
• As of July 6, 2024, there were 70,126 trials registered with CTRI, making it one of the world's largest national registries. A 2024 peer-reviewed study found 88 % of CDSCO-approved trials had compliant CTRI records. This high level of registration and compliance is strengthening India’s position as a trusted global destination for clinical trials, improving transparency, regulatory confidence, and data reliability. It is also encouraging more global pharma companies to conduct trials in India, as structured documentation reduces approval risks and improves trial efficiency.

India Healthcare Market Scope

Category	Segments
By Healthcare Expenditure Type	Public Healthcare Expenditure, Private Healthcare Expenditure, Out-of-Pocket Expenditure
By Pharmaceutical Segment	Prescription Drugs, Over-the-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologics & Biosimilars
By Therapeutic Area	Cardiovascular Diseases, Oncology, Diabetes, Respiratory Diseases, Neurology, Infectious Diseases, Others
By Medical Device Type	Diagnostic Imaging Devices, Patient Monitoring Devices, Surgical Equipment, In-vitro Diagnostics, Orthopedic Devices, Cardiovascular Devices, Others
By Technology Type	Artificial Intelligence in Healthcare, Telemedicine & Remote Monitoring, Electronic Health Records (EHR), Healthcare Analytics, Robotic Surgery, Wearables & Health Apps
By Healthcare Workforce	Physicians, Nurses, Dentists, Allied Health Professionals
By Insurance Type	Public Health Insurance, Private Health Insurance
By Disease Category	Chronic Diseases, Infectious Diseases, Mental Health Disorders
By End User	Hospitals, Clinics, Diagnostic Centers / Laboratories, Ambulatory Surgical Centers, Home Healthcare, Research Institutes, Pharmacies, Others

India Healthcare Sector Growth Drivers

Rising Burden of Non-Communicable Diseases Driving Sustained Healthcare Demand Expansion

India’s healthcare demand is structurally driven by the rapid rise in non-communicable diseases (NCDs), which has intensified due to urbanization, sedentary lifestyles, and aging demographics. According to the World Health Organization, NCDs account for 63% of total deaths in India, with cardiovascular diseases being the leading cause. This epidemiological shift is increasing the need for long-term treatment, continuous diagnostics, and hospital-based care.

The demand impact is evident across hospitals and diagnostic centers, where chronic disease cases are rising consistently. As per the Indian Council of Medical Research, India Diabetes Study, India has 101 million people living with diabetes , reflecting a sharp increase in chronic disease burden. Additionally, cancer incidence is projected to rise to 1.57 million cases by 2025, increasing demand for oncology infrastructure and specialized care services.

This driver is materially expanding market volume rather than merely influencing pricing, as chronic diseases require repeated consultations, long-term medication, and continuous monitoring over several years. Public health initiatives such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke are increasing screening coverage and early diagnosis, leading to higher treatment uptake. Additionally, private healthcare providers are expanding capacity in specialty care segments to meet rising demand. This sustained increase in treatment cycles, hospital admissions, and diagnostic procedures is fundamentally enlarging the overall healthcare demand in India.

Recent Trends

AI-Based Diagnostic Automation Replacing Manual Screening and Radiology Workflows in India

India’s healthcare industry is witnessing a structural shift where AI-based diagnostic systems are replacing traditional manual screening and radiology interpretation processes. This transition has accelerated due to rising patient volumes and a shortage of skilled radiologists, particularly in high-burden disease areas. Deployments by organizations such as Qure.ai demonstrate large-scale automation, where AI tools process millions of chest X-rays for tuberculosis and lung abnormalities, reducing reliance on manual first-level reads.

AI-based screening is also replacing symptoms-based diagnosis, enabling frontline workers to diagnose, for instance, Swaasa AI conducted rural screening of 8,000 individuals using cough-based AI detection they identified 36% TB cases that were asymptomatic this eliminates need for traditional symptom-first screening approach.

This trend is fundamentally transforming hospital workflows by replacing subjective, time-intensive diagnostic processes with automated, standardized outputs. Hospitals such as Apollo Hospitals have integrated AI tools for radiology and imaging interpretation, enabling faster triaging and prioritization of critical cases. AI-driven screening solutions are now capable of handling high daily scan volumes, significantly reducing turnaround time and allowing clinicians to focus on complex diagnoses rather than routine case evaluations.

The persistence of this trend is driven by its measurable impact on scalability and access, particularly in underserved regions with limited specialist availability. Companies like Niramai are replacing conventional diagnostic methods such as mammography with AI-based thermal imaging solutions, enabling non-invasive and scalable screening. As AI continues to automate high-volume diagnostic tasks, it is structurally redefining care delivery models and is expected to remain a long-term driver of healthcare system transformation in India.

Opportunities and Challenges

Data Security and Privacy Risks Driving Cybersecurity Investment and Compliance-Led Health-Tech Expansion

India’s healthcare industry is increasingly exposed to cybersecurity risks as large-scale digitization of health records accelerates under national digital health initiatives. Hospitals, insurers, and digital platforms are handling sensitive patient data through electronic health records (EHRs), making them attractive targets for cyberattacks. Incidents such as ransomware attacks on major hospital networks and data breaches in diagnostic platforms highlight systemic vulnerabilities. According to the India Cyber Threat Report, the healthcare sector accounted for 21.82% of all cyberattacks in India, making it the most targeted industry. Regulatory focus has intensified with the introduction of the Digital Personal Data Protection Act, which mandates stricter data handling, consent, and storage norms for healthcare entities.

Additionally, Indian healthcare organizations face extremely high attack frequency, with reports indicating over 8,614 cyberattacks per week on average , highlighting the scale of vulnerability. The severity of these risks is reflected in real-world incidents impacting healthcare operations and patient data. The ransomware attack on the All India Institute of Medical Sciences compromised over 40 million patient records and disrupted hospital services for weeks, demonstrating systemic cybersecurity gaps. Similarly, cyberattacks on hospitals in Delhi in 2025 led to the complete disruption of OPD and IPD services, forcing a shift to manual systems and exposing sensitive patient data.

This challenge is creating a strong opportunity for investment in healthcare-specific cybersecurity infrastructure and compliance solutions. Hospitals and health-tech firms are increasingly deploying encryption systems, secure cloud storage, and identity access management tools to protect patient data. For instance, Apollo expanded its partnership with Google Cloud to build a secure, cloud-based healthcare ecosystem (Apollo 24/7), integrating AI, digital records, and clinical decision systems. This includes secure data architecture, interoperability, and protected patient data exchange at scale. A collaboration between Indian Institute of Science and Wipro GE Healthcare is focused on advancing the development of secure healthcare technologies, with an emphasis on integrating cybersecurity into medical systems and digital health infrastructure. The initiative supports joint research, product innovation , and commercialization of next-generation healthcare solutions designed with built-in data protection capabilities.

This partnership is contributing to the emergence of a cybersecurity-enabled medtech innovation ecosystem in India, while also accelerating investments in healthcare products that incorporate robust data security frameworks. At the enterprise level, compliance with data protection regulations is creating a new market for specialized services such as consent management, data governance, and security infrastructure. Healthcare organizations are investing between USD 12,000 to 120,000 in cybersecurity systems alone, including encryption, access control, and threat detection tools.

These figures clearly show that increasing cyber risks and regulatory requirements are not just challenges they are actively driving new demand for cybersecurity solutions, compliance platforms, and health-tech security services, creating a scalable and long-term opportunity within India’s healthcare expenditure.

Epidemiology Profile

Diabetes:

Diabetes demonstrates structural dominance within India’s disease burden, driven by sustained epidemiological expansion and systemic healthcare demand. India hosts over 77 million adult diabetes cases, with prevalence exceeding 9% and a la rge undiagnosed population, indicating deep penetration across both urban and semi-urban populations. Incidence has shown a continuous rise, reaching over 264.5 cases per 100,000 population, while mortality rates have also steadily increased, reflecting inadequate disease control and late-stage diagnosis. This persistent growth establishes diabetes as a high-volume, long-duration disease segment with continuous treatment dependency.

Policy frameworks and healthcare investments further reinforce diabetes dominance through targeted national programs and infrastructure expansion. Government-led initiatives such as NPCDCS and integration under primary healthcare systems are increasing screening and diagnosis rates, thereby expanding the treated population pool, for example Over 700+ district NCD clinics and 5,000+ CHC-level clinics have been established for diabetes screening and management, also universal screening of the population above 30 years for diabetes under primary healthcare systems.

The treatment landscape for Diabetes Mellitus in India is structured around long-term glycemic control, complication prevention, and scalable primary care delivery, combining pharmaceuticals, devices, and digital health solutions. First-line therapy is dominated by oral anti-diabetic drugs such as Metformin, followed by sulfonylureas and newer classes like DPP-4 inhibitors and SGLT2 inhibitors for better cardiovascular outcomes. For advanced cases, insulin therapy, particularly analog insulin, plays a critical role, with increasing adoption driven by improved affordability programs and domestic manufacturing by companies like Biocon, which introduced low-cost biosimilar insulin at significantly reduced prices, expanding patient access and triggering price competition in the Indian market. The introduction of Ozempic (semaglutide) in India marks a significant advancement in the treatment landscape for type 2 diabetes, reflecting a shift toward next-generation, outcome-driven therapies. As a GLP-1 receptor agonist developed by Novo Nordisk, the drug offers improved glycemic control along with additional benefits such as weight reduction and cardiovascular risk mitigation. Its entry into the Indian market highlights the growing adoption of innovative biologic therapies beyond traditional oral drugs and insulin.

Therefore, this launch signals an expanding premium treatment segment, driven by rising patient awareness, increasing diagnosis of uncontrolled diabetes, and demand for therapies with multi-dimensional clinical benefits.

Cardiovascular Diseases:

Data from the Institute for Health Metrics and Evaluation Global Burden of Disease (GBD) 2023 estimates highlight the extensive spread of Cardiovascular Diseases in India. The total prevalent population reached approximately 77.8 million cases, representing 5.51% of the total population, with an age-standardized prevalence rate of 5,390 per 100,000 population. These figures indicate a substantial and widely distributed disease burden across all age groups, reinforcing its position as a leading chronic condition in the country.

From an incidence standpoint, India recorded nearly 7.83 million new cardiovascular cases in 2023, translating to an incidence rate of 542 per 100,000 population. While the percentage incidence appears relatively low at 0.12%, the absolute number of new cases remains significantly high due to the country’s large population base. This continuous inflow of new patients contributes to the expanding disease pool and sustained pressure on healthcare systems.

India’s cardiovascular treatment landscape is rapidly evolving beyond conventional care models, with emerging innovations in AI-driven diagnostics, advanced medical devices, and integrated care delivery creating new avenues for scalable and high-value healthcare solutions. For instance,

AI-enabled imaging technologies , including AI-based OCT and advanced catheter-based imaging systems, are increasingly being adopted to enhance the accuracy of angioplasty and other interventional cardiac procedures. These tools are being integrated into clinical practice to support more precise decision-making during complex cardiovascular interventions.

Kauvery Hospitals has introduced a significant shift in cardiovascular care delivery by establishing India’s first AI-driven Advanced Heart Failure Centre, marking a transition toward technology-enabled integrated care models. The facility combines artificial intelligence, IoT-based patient monitoring, and predictive analytics to support clinical decision-making and continuous patient tracking. India now uses drug-eluting stents (DES) for coronary artery disease; new-generation stents release anti-proliferative drugs to prevent artery re-blockage (restenosis). Indian hospitals are increasingly using bioresorbable and ultra-thin strut stents.

India Healthcare Market News and Recent Developments

2026: India’s First Government AI Clinic Inaugurated at GIMS, Greater Noida

The Government Institute of Medical Sciences (GIMS), Greater Noida has launched India’s first government-run AI-powered clinic. The facility integrates artificial intelligence with genetic screening to support early detection and treatment of critical illnesses such as cancer, cardiovascular diseases, kidney, and liver disorders. The system analyzes medical data including blood tests, imaging scans, X-rays, CT scans, and MRI reports to assist doctors in diagnosis and treatment planning. It also supports AI-assisted robotic surgery, improving precision in complex procedures. The initiative aims to reduce delays in diagnosis and improve treatment outcomes, especially for critically ill patients in public healthcare settings.

Impact Analysis: This development marks a structural shift in India’s public healthcare delivery model by integrating AI into routine clinical decision-making. It strengthens early disease detection capabilities, particularly for high-burden conditions like cardiovascular diseases and cancer. The initiative improves diagnostic efficiency, reduces human error, and enhances treatment precision, leading to better patient outcomes. It also creates a scalable framework for AI adoption in government hospitals across other states. From a market perspective, it opens opportunities for AI healthcare platforms, diagnostic technology providers, and med-tech startups. Overall, it signals a transition toward technology-driven, data-centric healthcare infrastructure in India.

2026: AIIMS Patna Partners With C-DAC to Deploy AI-Powered Healthcare and Cybersecurity Systems

AIIMS has signed a collaboration with Centre for Development of Advanced Computing to deploy AI-powered healthcare systems along with advanced cybersecurity infrastructure. The partnership aims to integrate artificial intelligence into clinical workflows, hospital operations, and patient data management systems.

Under this initiative, AI tools will support diagnosis through imaging analysis (X-ray, MRI, CT scans), clinical decision support systems, and predictive health analytics for early disease detection. The collaboration also includes development of smart hospital systems to improve efficiency in patient registration, scheduling, and treatment workflows. A key component of the project is the establishment of an Artificial Intelligence Special Purpose Hub (AI-SPH), which will function as a centre for research, innovation, and training in AI-based healthcare applications. The initiative also places strong emphasis on cybersecurity systems to protect sensitive patient data and prevent cyber threats in increasingly digital hospital environments

Impact analysis: This partnership accelerates adoption of AI-based diagnostics and hospital automation in India’s public healthcare system, improving speed and accuracy of treatment. It strengthens data security frameworks, which is critical as hospitals move toward digital records and AI-driven systems. The initiative also sets a model for other government hospitals to integrate AI into clinical workflows. It creates demand for health-tech solutions, AI software, and cybersecurity infrastructure in healthcare. Overall, it supports the shift toward a more efficient, tech-enabled, and scalable public health system.

2025: Curapod Launch – India’s First Personalized Wearable for Drug-Free Pain Relief

Curapod, developed by Litemed India, has launched India’s first personalized wearable device for non-invasive, drug-free pain management. The device uses photobiomodulation technology, which delivers controlled red and near-infrared light to affected areas to reduce inflammation, stimulate cellular repair, and support recovery from musculoskeletal pain. It is designed to address more than 30 conditions, including chronic back pain, arthritis, joint pain, and sports injuries.

The wearable is registered with both CDSCO (India’s drug regulator) and the US FDA, indicating regulatory validation for medical use. It also includes an adaptive therapy system, which adjusts intensity based on user response, along with a mobile application for tracking pain levels and treatment progress.

The product is already being adopted by physiotherapy centers and wellness clinics, while also targeting home users seeking alternatives to long-term medication use. It is positioned as a portable, home-use medical device that brings clinical-grade pain management into everyday settings.

Impact Analysis: This launch strengthens India’s wearable med-tech and non-invasive therapy segment, especially in chronic musculoskeletal pain management. It reflects growing demand for drug-free alternatives, driven by concerns over long-term painkiller use and side effects. From a market perspective, it opens opportunities in digital therapeutics, wearable health devices, and physiotherapy-tech integration, especially for home-based care models. It also supports the shift from hospital-centric treatment to continuous, patient-managed care.

Additionally, the use of photobiomodulation and adaptive therapy systems indicates increasing adoption of light-based and AI-supported medical devices, creating scope for innovation in smart recovery and rehabilitation technologies. Overall, it signals a broader transition toward portable, personalized, and non-pharmacological pain management solutions in India’s healthcare ecosystem.

2024: JNCASR Flexible Near-Infrared Devices for Healthcare Innovation

The Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru has developed flexible near-infrared (NIR) plasmonic devices aimed at next-generation medical sensing and imaging applications. These devices are engineered using cost-efficient materials such as scandium nitride, enabling high-performance optical sensing at lower production costs. The innovation is positioned as a breakthrough in biomedical engineering, particularly for diagnostic and monitoring applications.

The technology is designed for use in wearable health sensors, advanced biomedical imaging systems, and real-time diagnostic tools, where near-infrared light is used to detect physiological and biochemical signals. The flexible structure allows the device to bend and adapt to different body surfaces, making it suitable for continuous patient monitoring and wearable healthcare applications. Unlike conventional rigid and expensive materials such as gold and silver, this innovation focuses on cost-effective, flexible, and scalable device architecture, improving accessibility of advanced diagnostic technologies. It supports India’s broader shift toward affordable, precision-based healthcare solutions.

Impact Analysis: This development strengthens India’s position in advanced medical imaging and wearable diagnostics technologies, enabling early disease detection and continuous health monitoring. It opens new opportunities in non-invasive diagnostics, smart wearable medical devices, and AI-integrated health monitoring systems. From a market perspective, it reduces dependency on expensive imported medical imaging components and supports domestic innovation in med-tech manufacturing. It also aligns with the rising demand for point-of-care diagnostics and remote patient monitoring solutions, especially in chronic diseases.

For the healthcare ecosystem, this innovation can improve early screening accuracy and patient accessibility in rural and semi-urban regions, where advanced imaging infrastructure is limited. Overall, it signals a shift toward low-cost, high-precision, and scalable diagnostic technologies in India’s healthcare system.

India’s Major Healthcare Cluster Cities and Infrastructure Hubs

• Bengaluru: Wipro GE Healthcare is investing USD 960 million in India with Bengaluru as a core hub to build CT scanners, PET-CT systems, and advanced diagnostic devices for global export. Strengthening India’s role in global medical device supply chains. Takeda and other global pharma firms setting up AI-driven centres in Bengaluru is shifting the healthcare ecosystem from hospital-led care to data and AI-led drug development.This will increase investment in drug discovery, clinical trials, and health data analytics, while reducing time-to-market for new treatments.Overall, Bengaluru is evolving into a pharma-tech hub where growth is driven more by innovation and AI than just hospital expansion.
• Hyderabad: Witnessing a strategic shift toward advanced therapeutics through large-scale biopharma investments, highlighted by the establishment of a USD 75 million gene and cell therapy facility by Bharat Biotech in Genome Valley, aimed at developing next-generation treatments for oncology and genetic disorders. The city is advancing clinical innovation in diagnostic healthcare delivery, exemplified by initiatives Niloufer Hospital in Hyderabad introduced India’s first AI-based blood test system that gives results in under a minute without needles.
• Chennai: Tamil Nadu with Chennai as the core hub attracts 25% of India’s total medical tourists 1.5 million foreign patients annually, making it the single most important destination in India for international healthcare demand . Chennai has some of India’s highest volumes of kidney and liver transplants, with hospitals like Gleneagles Global Health City treating complex multi-organ failure cases referred from across India and abroad.
• Ahmedabad: Major hospital expansions like 500–1,000+ bed super-specialty facilities by Adani, Torrent, Zydus will significantly increase tre